YD-0293

Primary objective: To evaluate the safety and tolerability of single and multiple oral administration of YD0293 tablets in healthy subjects. Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of YD0293 tablets in healthy subjects after single and multiple oral administration; to evaluate the effect of food on the PK characteristics of YD0293 tablets in healthy subjects; to explore the effect of YD0293 tablets on the QT/QTc interval in healthy subjects; to evaluate the changes in neutrophil elastase (NE) concentration compared with baseline after multiple oral administration of YD0293 tablets in healthy subjects.